ArticleSSM - population health2026
Considerations for study design and analysis for ethically and culturally safe DNA methylation research in Aotearoa New Zealand.
Article in SSM - population health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Epigenetic research, particularly DNA methylation (DNAm), holds significant potential for improving cardiovascular disease (CVD) risk prediction, yet its application must be guided by ethical and culturally responsive considerations. This paper examines the integration of a values-based framework to ensure the culturally safe conduct of DNAm research within the Multi-Ethnic New Zealand Study of Acute Coronary Syndromes (MENZACS) cohort. Grounded in Te Tiriti o Waitangi principles and kaupapa Māori methodologies, this study emphasises equity, social accountability, and indigenous data sovereignty. This study was not designed as a discovery epigenome wide analysis, but rather performed, as an exemplar, a SWOT analysis that identified both the potential of DNAm markers, such as cg05575921 in AHRR for smoking exposure assessment, and key risks, including genetic confounding, population-specific variation, and the potential for individual and transgenerational stigma. Findings underscore the importance of ensuring multi-ethnic validation of DNAm markers to prevent exacerbation of health inequities. This paper advocates for the adoption of ethical, culturally attuned research frameworks in epigenetics to enhance equitable health outcomes and support Māori health advancement.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.